Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Salestools Logo

Salestools

El agente IA #1 para equipos de ventas y Go-to-Market. Vende más, más rápido, con menos esfuerzo.

Producto

  • Agentes de ventas IA
  • Datos de intención
  • Datos tecnológicos
  • Seguimiento de visitantes
  • Co-Pilot
  • Venta social

Soluciones

  • Servicio al cliente
  • Comercio electrónico
  • SaaS
  • Empresarial
  • Pequeña empresa

Recursos

  • El informe
  • Documentación
  • Referencia de API
  • Centro de ayuda
  • Blog
  • Casos de estudio
  • Webinars

Empresa

  • Acerca de
  • Carreras
  • Prensa
  • Contacto
  • Socios

Nuestras ubicaciones

  • Nueva York, HQ
  • Bucarest, laboratorio de investigación IA
  • Zug, Suiza

© 2026 Salestools. Todos los derechos reservados.

Términos de datos y seguridadPolítica de privacidadTérminos de servicioAcceptable Use
Todos los sistemas operativos
Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Back to Reports
Fundraising

Praxair

Praxair Raises $60B in Public

10 Riverview Drive, Danbury, CT 06810January 1, 20242 min read
Employees
26000+

Praxair Raises $60B in Public


Praxair has successfully raised $60B in a Public at a $65B valuation led by Linde.


Company Overview


Praxair is a Chemical company headquartered in 10 Riverview Drive, Danbury, CT 06810, founded in 1907 with 26000+ employees.


Industrial gases company


Fundraising Details


  • Amount Raised: $60B
  • Round Type: Public
  • Valuation: $65B
  • Date: 2024-01-01
  • Investors: Linde

About Praxair


Industrial gases company The company is positioned in the Chemical sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 10 Riverview Drive, Danbury, CT 06810
  • Founded: 1907
  • Team Size: 26000+
  • Industry: Chemical

What This Means


This funding round demonstrates strong investor confidence in Praxair's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Chemical sector continues to attract significant investment as companies innovate to meet evolving market demands. Praxair's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $65B valuation marks an important milestone for Praxair, positioning the company among notable players in the Chemical industry.


Looking Ahead


With this new capital, Praxair is well-positioned to execute on its growth strategy and continue building innovative solutions in the Chemical space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Praxair, visit their headquarters at 10 Riverview Drive, Danbury, CT 06810.

Company Info

Headquarters
10 Riverview Drive, Danbury, CT 06810
Founded
1907
Team Size
26000+

Topics

Fundraising(2912)Public(771)ChemicalPraxair

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free